Home » Stocks » Cellectar BioSciences

Cellectar BioSciences, Inc. (CLRB)

Stock Price: $1.40 USD 0.00 (0.00%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 33.60M
Revenue (ttm) n/a
Net Income (ttm) -14.43M
Shares Out 24.00M
EPS (ttm) -1.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $1.40
Previous Close $1.40
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.40
Day's Range 1.38 - 1.42
Day's Volume 423,366
52-Week Range 1.01 - 3.33

More Stats

Market Cap 33.60M
Enterprise Value 27.01M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 24.00M
Float 7.88M
EPS (basic) -1.63
EPS (diluted) -1.63
FCF / Share -1.32
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 92,954
Short Ratio 0.38
Short % of Float 1.22%
Beta 1.73
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 8.32
Revenue n/a
Operating Income -14.51M
Net Income -14.43M
Free Cash Flow -12.42M
Net Cash 6.59M
Net Cash / Share 0.27
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -84.91%
ROE -191.20%
ROIC 4,015.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.48*
(291.43% upside)
Low
3.00
Current: $1.40
High
10.00
Target: 5.48
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-14.18-13.33-13.60-9.45-8.76-9.89-12.40-8.75-7.04-4.19
Net Income-14.09-13.24-13.56-6.18-5.50-8.05-10.78-8.80-7.44-4.56
Shares Outstanding7.682.961.400.440.080.050.030.020.010.01
Earnings Per Share-1.84-5.23-10.70-21.40-70.30-175.30-386.00-460.00-620.00-720.00
Operating Cash Flow-11.69-11.44-11.02-8.28-8.21-8.84-9.15-6.59-5.97-3.38
Capital Expenditures-0.02-0.33-0.35-0.07-0.06-0.03-0.15-0.10-0.12-
Free Cash Flow-11.72-11.77-11.37-8.35-8.27-8.87-9.30-6.68-6.09-3.38
Cash & Equivalents10.6113.3110.0611.503.919.482.476.735.561.23
Total Debt0.53-0.010.090.340.460.450.450.463.86
Net Cash / Debt10.0913.3110.0611.413.579.012.026.285.10-2.63
Assets12.2515.0512.8715.327.6013.426.8211.4810.564.80
Liabilities3.191.792.121.785.956.725.121.321.084.67
Book Value9.0613.2610.7513.541.656.701.7010.169.480.13
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cellectar BioSciences, Inc.
Country United States
Employees 8
CEO James V. Caruso

Stock Information

Ticker Symbol CLRB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CLRB

Description

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.